Last reviewed · How we verify
ARV-110 in Combination with Abiraterone
Androgen receptor inhibitor
ARV-110, a PROTAC degrader of the androgen receptor, is being evaluated in combination with abiraterone for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 trial has been completed with promising safety and efficacy data, positioning it as a potential best-in-class therapy.
At a glance
| Generic name | ARV-110 in Combination with Abiraterone |
|---|---|
| Sponsor | Arvinas Androgen Receptor, Inc. |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ARV-110 is a selective androgen receptor degrader (SARD) that targets the androgen receptor, a protein that plays a key role in the growth and spread of prostate cancer cells.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Hypertension
- Diarrhea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: